December 13, 2025 06:31 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Caught in Thailand! Fugitive Goa nightclub owners detained after deadly fire kills 25 | After Putin’s blockbuster Delhi visit, Modi set to host German Chancellor Friedrich Merz in January | Delhi High Court slams govt, orders swift compensation as IndiGo crisis triggers fare shock and nationwide chaos | Amazon drops a massive $35 billion India bet! AI push, 1 million jobs and big plans revealed at Smbhav Summit | IndiGo’s ‘All OK’ claim falls apart! Govt slaps 10% flight cut after weeklong chaos | Centre finally aligns IndiGo flights with airline's operating ability, cuts its winter schedule by 5% | Odisha's Malkangiri in flames: Tribals rampage Bangladeshi settlers village after beheading horror! | Race against time! Indian Navy sends four more warships to Cyclone Ditwah-hit Sri Lanka | $2 billion mega deal! HD Hyundai to build shipyard in Tamil Nadu — a game changer for India | After 8 years of legal drama, Malayalam actor Dileep acquitted in 2017 rape case — what really happened?
Japan I Covid19
Image Cr: Unsplash

Japan approves home-made Covid-19 cure for emergency use

| @indiablooms | Nov 24, 2022, at 06:44 pm

Tokyo/UNI: The Japanese Health Ministry has authorised the island nation's first locally made COVID-19 oral treatment, Xocova, for emergency use.

This emergency approval was granted on the anticipated efficacy of Xocova and the acceptability of its safety profile based on the results obtained through the Phase 2 part (497 cases including the Phase 2a and Phase 2b parts combined) and the Phase 3 part (1,821 cases) of the Phase 2/3 study.

The pill was developed by Osaka-based pharmaceutical firm Shionogi & Co to treat coronavirus patients after they develop initial symptoms, such as fever, cough, a sore throat, a runny nose, and fatigue.

Xocova is an oral antiviral agent administered once daily for five days that suppresses the replication of SARS-CoV-2 by selectively inhibiting the viral 3CL protease.

It has been proven the most effective when administered during the first three days of symptoms starting.

The drug is known to reduce the viral load to three percent when taken on day four, and is not recommended for use during pregnancy.

Shionogi had filed for manufacturing and sales approval on Feb. 25, 2020.

The company said it had enough pills to treat one million people, and the drug will hit the shelves in Dec.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.